var quotes=new Array()

//change the quotes if desired. Add/ delete additional quotes as desired.

quotes[0]='IRX Therapeutics was founded by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology.'

quotes[1]='IRX Therapeutics\' product platform seeks to restore an effective cellular immune response for the treatment of advanced cancers and viral diseases.'

quotes[2]='IRX Therapeutics has raised over $65 million from investors.'

quotes[3]='IRX Therapeutics is led by an experienced management team.'

quotes[4]='The Company\'s advisors include key opinion leaders in the oncology community.'

quotes[5]='IRX-2 has been studied in Phase 1 and Phase 2 clinical trials.'

quotes[6]='IRX Therapeutics is preparing to launch the INSPIRE trial, a global pivotal Phase 3 clinical trial in head and neck cancer.'

quotes[7]='IRX-2 has been granted Fast Track designation in the U.S.'

quotes[8]='IRX-2 is the Company\'s lead cancer therapy in development for Head and Neck Cancer.'

quotes[9]='IRX-2 is a primary cell-derived biologic with multiple active components.'

quotes[10]='IRX-4 is in development for the treatment of prostate cancer. IRX-4 is a combination of IRX-2 and prostate specific antigens.'

quotes[11]='IRX-3 is the combination of IRX-2 and an immunostimulatory peptide.'

quotes[12]='MIMP is the Company\'s anti-viral, small molecule product candidate.'

quotes[13]='The complex nature of the immune system suggests that multiple active components are needed to effectively address the immune depression and suppression challenges of advanced cancers and viruses.'

quotes[14]='Immune depression is characterized by reduced T cell number and function and the defective function of monocyte/macrophages and antigen-processing dendritic cells. '

quotes[15]='IRX Therapeutics proprietary technologies stimulate dendritic cells, macrophages, and T cells by initiating a Th1-specific cellular immune response.'

quotes[16]='IRX Therapeutics believes that its drugs under development, including IRX-2 are broadly applicable to a number of cancers beyond the initial indication of head and neck cancer being sought for IRX-2.'

quotes[17]='IRX Therapeutics raised $25 million in a Series A convertible preferred stock in May 2008.'

quotes[18]='IRX Therapeutics presented initial Phase 2 findings of IRX-2 at the prestigious 7th International Conference of the American Head & Neck Society in July 2008.'

var whichquote=Math.floor(Math.random()*(quotes.length))
document.write(quotes[whichquote])